glaumox acetazolamide (as sodium) 500 mg powder for injection vial
phebra pty ltd - acetazolamide sodium, quantity: 549.5 mg (equivalent: acetazolamide, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - for adjunctive treatment of: oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.
parecoxib juno parecoxib (as sodium) 40 mg powder for injection vial
juno pharmaceuticals pty ltd - parecoxib sodium, quantity: 42.36 mg - injection, powder for - excipient ingredients: dibasic sodium phosphate; phosphoric acid; sodium hydroxide - for a single peri-operative dose for the management of post-operative pain.
parecoxib juno parecoxib (as sodium) 40 mg powder for injection vial with diluent
juno pharmaceuticals pty ltd - parecoxib sodium, quantity: 42.36 mg - injection, powder for - excipient ingredients: phosphoric acid; dibasic sodium phosphate; sodium hydroxide - for a single peri-operative dose for the management of post-operative pain.
veletri epoprostenol (as sodium) 500 microgram powder for injection vial
janssen-cilag pty ltd - epoprostenol sodium, quantity: 531 microgram (equivalent: epoprostenol, qty 500 microgram) - powder - excipient ingredients: arginine; sodium hydroxide; sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with:,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with the scleroderma spectrum of diseases
veletri epoprostenol (as sodium) 1.5 mg powder for injection vial
janssen-cilag pty ltd - epoprostenol sodium, quantity: 1.593 mg (equivalent: epoprostenol, qty 1.5 mg) - powder - excipient ingredients: arginine; sodium hydroxide; sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with:,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with the scleroderma spectrum of diseases
parecoxib-aft parecoxib (as sodium) 40 mg powder for injection vial
aft pharmaceuticals pty ltd - parecoxib sodium, quantity: 42.36 mg (equivalent: parecoxib, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; dibasic sodium phosphate; phosphoric acid - for a single peri-operative dose for the management of post-operative pain
abraxane nanoparticle albumin-bound paclitaxel 100 mg powder for injection (suspension) vial
abraxis bioscience australia pty ltd - paclitaxel, quantity: 100 mg - injection, powder for - excipient ingredients: albumin; sodium octanoate; sodium acetyltryptophanate - metastatic breast cancer abraxane is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. non-small cell lung cancer abraxane, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation. metastatic adenocarcinoma of the pancreas abraxane, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.
abraxane nanoparticle albumin-bound paclitaxel 250 mg powder for injection (suspension) vial
abraxis bioscience australia pty ltd - paclitaxel, quantity: 250 mg - injection, powder for - excipient ingredients: albumin; sodium octanoate; sodium acetyltryptophanate - metastatic breast cancer abraxane is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. non-small cell lung cancer abraxane, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation. metastatic adenocarcinoma of the pancreas abraxane, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.
lucrin depot 7.5mg powder for injection prefilled dual-chamber syringe with 23 g needle
abbvie pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: gelatin; mannitol; polyglactin - lucrin depot 7.5 mg injection and lucrin depot 3 month 22.5mg injection and lucrin depot 4 month 30mg injection are indicated in the palliative treatment of metastatic or locally extensive prostatic cancer (stage c and d).
ganciclovir sxp ganciclovir (as sodium) 500 mg powder for injection vial
southern cross pharma pty ltd - ganciclovir sodium, quantity: 546 mg (equivalent: ganciclovir, qty 500 mg) - injection, powder for - excipient ingredients: - ganciclovir sxp (ganciclovir) administered as the iv infusion is indicated for the palliative treatment of confirmed sight-threatening cytomegalovirus (cmv) disease in aids and other severely immunocompromised individuals. it is indicated for the treatment of confirmed cmv pneumonitis in bone marrow transplant patients. it is also indicated for the prophylaxis of cmv infection and disease following bone marrow and solid organ transplantation in patients at risk of cmv disease.,note: ganciclovir sxp (ganciclovir) is not indicated for congenital or neonatal cmv disease; nor for the treatment of cmv infection in non-immunocompromised individuals.